Genasense Gets Second Chance As Genta Completes Chronic Leukemia NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Genta hopes confirmatory trial to support accelerated approval will use different regimen combining Genasense with Rituxan and chemotherapy.
You may also be interested in...
Genta Plans Genasense Confirmatory Trial In Treatment-Naive Patients
With approval possible in June for relapsed or refractory leukemia, Genta is seeking a marketing partner for oblimersen.
Genta Plans Genasense Confirmatory Trial In Treatment-Naive Patients
With approval possible in June for relapsed or refractory leukemia, Genta is seeking a marketing partner for oblimersen.
Genasense Phase III Trial In Multiple Myeloma Fails
Genta says it will analyze the trial data “in considerably more detail before making decisions regarding the Genasense program in myeloma.” News of the failed trial comes on the heels of a separate Phase III study of oblimersen in chronic lymphocytic leukemia that met its primary endpoint but failed to show a survival benefit.